$2.4 B

PTCT Mkt cap, 10-Jun-2019

$53.6 M

PTC Therapeutics Revenue Q1, 2019
PTC Therapeutics EBIT (Q1, 2019)-69.1 M
PTC Therapeutics Cash, 31-Mar-2019201.1 M
PTC Therapeutics EV2.4 B

PTC Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

34.7m25.2m36.8m82.7m194.4m264.7m

Revenue growth, %

(27%)46%125%

R&D expense

54.9m121.8m117.6m117.5m172.0m

General and administrative expense

25.2m82.1m97.1m121.3m153.5m

Operating expense total

80.1m203.9m214.8m258.7m380.4m

EBIT

(45.4m)(99.4m)(167.1m)(132.1m)(64.3m)(115.7m)

EBIT margin, %

(131%)(394%)(455%)(160%)(33%)(44%)

Interest expense

6.1m1.2m2.4m8.3m12.1m12.6m

Interest income

1.2m

Pre tax profit

(77.7m)(128.1m)

Income tax expense

(485.0k)(569.0k)(1.3m)29.0k

Net Income

(51.6m)(93.8m)(170.4m)(142.1m)

PTC Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

15.4m49.7m58.0m58.3m111.8m169.5m

Accounts Receivable

11.1m24.9m40.4m67.9m

Inventories

1.6m3.9m5.9m4.7m10.8m16.1m

Current Assets

145.0m323.6m355.9m261.3m249.1m320.9m

PP&E

6.7m9.0m8.4m12.7m

Goodwill

82.3m

Total Assets

151.9m333.2m368.0m269.3m391.7m1.1b

Accounts Payable

12.2m29.1m45.2m48.8m76.4m128.2m

Short-term debt

48.6k49.0k11.7m

Current Liabilities

13.1m32.5m45.4m49.6m82.0m166.8m

Long-term debt

94.6m98.2m145.0m141.3m

Total Debt

48.6k94.6m98.2m145.0m153.0m

Total Liabilities

15.4m142.0m149.8m235.2m768.5m

Additional Paid-in Capital

465.2m721.7m820.2m856.1m966.5m1.3b

Retained Earnings

(328.8m)(422.6m)(593.0m)(735.1m)(814.1m)(938.9m)

Total Equity

136.5m298.5m226.0m119.6m156.4m350.7m

Debt to Equity Ratio

0.8 x0.9 x

Debt to Assets Ratio

0.4 x0.4 x

Financial Leverage

1.1 x1.1 x1.6 x2.3 x2.5 x3.2 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

24.0m115.9m21.2m52.9m36.8m29.2m140.7m40.2m35.7m50.3m54.1m133.0m141.8m97.7m223.8m206.9m201.1m

Accounts Receivable

22.6m19.8m27.4m32.2m33.8m38.7m45.6m59.4m42.2m46.4m

Inventories

1.4m6.9m7.8m12.4m13.9m13.7m16.2m

Current Assets

160.1m249.4m230.3m213.5m289.8m264.6m384.2m326.4m297.4m280.6m240.7m227.0m221.3m242.0m375.6m313.3m479.1m

PP&E

6.9m6.3m6.4m6.2m9.0m8.8m8.4m7.6m7.1m7.1m6.8m6.9m8.3m8.2m8.8m14.5m

Goodwill

100.3m82.3m

Total Assets

167.2m255.8m237.6m220.8m299.5m273.8m396.1m335.2m305.6m288.2m248.6m383.1m367.7m379.4m511.8m1.0b1.3b

Accounts Payable

10.2m8.7m11.3m16.5m23.5m23.1m31.7m43.5m42.2m47.8m45.2m64.0m64.1m71.4m82.5m102.8m98.5m

Short-term debt

84.2k12.0k1.7m6.7m16.7m

Current Liabilities

13.9m9.2m11.6m17.3m23.9m23.1m31.7m43.9m42.9m48.9m45.4m68.0m71.9m72.7m86.5m114.9m143.0m

Long-term debt

93.2m93.4m94.9m96.6m99.9m141.2m143.1m146.9m147.2m144.3m138.5m

Total Debt

84.2k12.0k93.2m93.4m94.9m96.6m99.9m141.2m143.1m146.9m148.9m150.9m155.1m

Total Liabilities

16.2m11.5m13.8m19.5m26.2m25.2m126.9m139.2m139.9m148.0m147.8m213.3m221.8m229.1m244.4m642.5m771.0m

Additional Paid-in Capital

462.0m587.1m591.6m596.6m734.5m747.9m812.3m829.1m837.9m847.7m865.8m949.3m958.2m975.4m1.1b1.3b1.5b

Retained Earnings

(310.9m)(342.9m)(368.0m)(395.3m)(460.5m)(498.8m)(542.0m)(634.2m)(673.1m)(708.3m)(764.2m)(781.6m)(815.4m)(830.1m)(839.6m)(890.6m)(1.0b)

Total Equity

244.3m223.8m201.3m273.3m248.6m269.2m196.0m165.6m140.2m100.8m169.7m145.9m150.3m267.4m386.1m512.9m

Debt to Equity Ratio

0 x0.3 x0.5 x0.6 x0.7 x1 x0.8 x1 x0.6 x0.4 x

Debt to Assets Ratio

0 x0 x0.2 x0.3 x0.3 x0.3 x0.4 x0.4 x0.4 x0.3 x0.1 x

Financial Leverage

1 x1.1 x1.1 x1.1 x1.1 x1.5 x1.7 x1.8 x2.1 x2.5 x2.3 x2.5 x2.5 x1.9 x2.7 x2.5 x

PTC Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(51.6m)(93.8m)(170.4m)(142.1m)(79.0m)(128.1m)

Depreciation and Amortization

2.4m2.2m2.9m3.3m17.7m26.1m

Accounts Receivable

(6.9m)(14.8m)(12.2m)(29.6m)

Inventories

(760.5k)(2.3m)(2.1m)1.2m

Accounts Payable

5.2m16.9m17.0m4.3m24.0m43.9m

Cash From Operating Activities

(46.9m)(57.3m)(124.3m)(103.6m)(10.1m)(27.6m)

Cash From Investing Activities

(127.8m)(145.2m)(20.8m)104.5m13.1m(42.6m)

Long-term Borrowings

(5.0m)(49.0k)(49.0k)

Cash From Financing Activities

187.4m237.1m154.1m968.0k44.2m131.6m

Interest Paid

367.1k1.0k1.0k4.5m6.3m7.8m

Income Taxes Paid

2.1k2.0k111.0k943.0k1.1m1.6m

PTC Therapeutics Ratios

USDY, 2019

EV/EBIT

-34 x

EV/CFO

-55.5 x

Financial Leverage

2.5 x

PTC Therapeutics Employee Rating

2.933 votes
Culture & Values
3.1
Work/Life Balance
2.9
Senior Management
2.6
Salary & Benefits
3.7
Career Opportunities
2.9
Source